Vaccination with Attenuated Neisseria meningitidis Strains Protects against Challenge with Live Meningococci
AUTOR(ES)
Li, Yanwen
FONTE
American Society for Microbiology
RESUMO
Meningococcal disease is a life-threatening infection caused by Neisseria meningitidis. Currently, there are no vaccines to prevent infection with serogroup B N. meningitidis strains, the leading cause of meningococcal meningitis in Europe and North America. Here we describe the construction and characterization of two attenuated serogroup B N. meningitidis strains, YH102 (MC58Δsia ΔrfaF) and YH103 (MC58Δsia ΔmetH). Both strains are markedly attenuated in their capacity to cause bacteremia in rodent models and have a reduced ability to survive in a human whole-blood assay. Immunization of adult mice with these strains leads to the development of bactericidal antibodies and confers sterilizing protection against challenge with homologous live bacteria. Furthermore, we show that the strains confer protection against infection by other serogroups. Use of the attenuated strains in animals with gene knockouts or after depletion of immunological effectors could be used to define the basis of protection, and human volunteer studies could be undertaken to examine the immune response following exposure to this important human pathogen.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=344009Documentos Relacionados
- Protection against Establishment of Retroviral Persistence by Vaccination with a Live Attenuated Virus
- Protection by Live, Attenuated Simian Immunodeficiency Virus against Heterologous Challenge
- Vaccination with an Ostertagia ostertagi Polyprotein Allergen Protects Calves against Homologous Challenge Infection
- Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge
- Vaccination against Anthrax with Attenuated Recombinant Strains of Bacillus anthracis That Produce Protective Antigen